1. Introduction {#sec1-brainsci-07-00014}
===============

Morphine is a potent analgesic that is widely used clinically for pain management. However, long-term use of morphine can lead to morphine tolerance and addiction \[[@B1-brainsci-07-00014]\]. In addition, morphine can profoundly and detrimentally affect the body's immune system, at both the cellular and molecular levels. Morphine suppresses lymphocyte trafficking; decreases natural killer cell activity; inhibits the production of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β) \[[@B2-brainsci-07-00014],[@B3-brainsci-07-00014],[@B4-brainsci-07-00014]\]; and induces atrophy of immune organs, such as the spleen and thymus \[[@B5-brainsci-07-00014],[@B6-brainsci-07-00014],[@B7-brainsci-07-00014],[@B8-brainsci-07-00014],[@B9-brainsci-07-00014]\].

Morphine-induced immunosuppression significantly increases the risk of bacterial infection \[[@B10-brainsci-07-00014]\]. Although the immunosuppressive effects of morphine have been widely studied, the mechanisms involved in the body's inflammatory response to pathogens during morphine tolerance have not been fully investigated.

Inflammasomes are multi-protein complexes assembled from nucleotide oligomerization domain receptor proteins known as nucleotide-binding oligomerization domain (NOD)-like receptors (NLR) \[[@B11-brainsci-07-00014]\]. They function as important mediators of innate immunity. Inflammasomes play a key role in the regulation of inflammation and immune responses by participating in the production of pro-inflammatory cytokines, including IL-1β and interleukin-18 (IL-18) \[[@B11-brainsci-07-00014],[@B12-brainsci-07-00014],[@B13-brainsci-07-00014]\]. Both IL-1β and IL-18 produce a wide variety of biological effects associated with infection, inflammation, and autoimmune processes.

There have been about 20 NLR inflammasomes identified in humans. The most commonly studied ones include NLR Family Pyrin Domain Containing 1 (NLPR1), NLR family apoptosis inhibitory protein 6 (NAIP2), NLR Family Pyrin Domain Containing 3 (NLRP3), NLR Family Pyrin Domain Containing 5 (NLRP5), NLR Family Pyrin Domain Containing 6 (NLRP6), NLR Family Pyrin Domain Containing 12 (NLRP12), NLR family member X1 (NLRPX1), and NLR Family CARD Domain Containing 4 (NLRC4) \[[@B14-brainsci-07-00014]\]. Inflammasomes have been sub-divided into two groups; pro-inflammatory inflammasomes and anti-inflammatory inflammasomes. The pro-inflammatory inflammasomes include NLRP3 and NLRC4, and their functions have been widely studied. The anti-inflammatory inflammasomes include NLRP12, NLRX1, NLRC3, and NLRC5. They appear to function by limiting or suppressing a pro-inflammatory response; however, this group has not been well studied to date.

There have been a few recent reports characterizing the anti-inflammatory properties of NLRP12 \[[@B15-brainsci-07-00014],[@B16-brainsci-07-00014]\]. NLRP12 can inhibit NF-κB signaling through both the canonical and non-canonical pathways, which are important in the control and regulation of innate immune responses \[[@B15-brainsci-07-00014],[@B16-brainsci-07-00014]\]. NLRP12 inhibits IL-1 receptor-associated kinase 1 (IRAK1), a downstream component of the pathogen activated Toll-like receptor (TLR) pathway, which, in turn, decreases the signaling of the canonical NF-κB pathway \[[@B17-brainsci-07-00014]\]. In the non-canonical NF-κB pathway, NLRP12 interacts with and rapidly degrades NF-κB-inducing kinase (NIK), thereby suppressing NF-κB signaling \[[@B18-brainsci-07-00014]\].

The Library of Integrated Network-Based Cellular Signatures (LINCS) \[[@B19-brainsci-07-00014]\] is a database which implements a biological network-based strategy to make assessments regarding the impact of drugs, genetics, and related biological perturbations (alterations induced by external or internal mechanisms) on cellular states. The library database is based on the philosophy that typical human pathology, biology, and pharmacology are most aptly understood using a systems-level approach. It was constructed to generate a robust approach for perturbing a diversity of cell types, measuring cellular responses, integrating and analyzing data, and visualizing and interrogating the database for a variety of biomedical research applications \[[@B19-brainsci-07-00014]\]. This library allows researchers to access a wide variety of data by using a matrix consisting of cell type by experimental treatment by phenotypic assay. Using LINCS, researchers are able to inquire about information regarding mechanism-based relationships among the effects of different drug responses and their targets (perturbents) as well as associations among responding cellular components, in the format of network interactions and structure-function relationships \[[@B20-brainsci-07-00014]\].

In this study, we used an inflammasome PCR array containing 84 inflammasome-related genes to investigate the expression of inflammasomes during an inflammatory response to the bacterial endotoxin, lipopolysaccharide (LPS), in the rat brain during morphine tolerance. LINCS was then used to project possible candidate targets from the mRNA gene expression profiles generated from the PCR array analysis.

2. Materials and Methods {#sec2-brainsci-07-00014}
========================

2.1. Animals {#sec2dot1-brainsci-07-00014}
------------

Fisher/NHsd 344 (F344) rats were purchased from Harlan Laboratories (Indianapolis, IN, USA). The animals were housed in groups of 3--5 animals in a temperature controlled (21 °C--22 °C) animal holding room, under a 12-h light/12-h dark illumination cycle (lights on at 7:00 a.m.). Food and tap water were provided ad libitum. The Institutional Animal Care and Use Committee (IACUC) at Seton Hall University, South Orange, NJ, USA approved the experimental protocol.

2.2. Morphine and LPS Administration {#sec2dot2-brainsci-07-00014}
------------------------------------

A 2 + 4 regimen was used to produce morphine tolerance in 7--8 mo old (250--350 g) male F344 rats \[[@B5-brainsci-07-00014],[@B21-brainsci-07-00014],[@B22-brainsci-07-00014],[@B23-brainsci-07-00014],[@B24-brainsci-07-00014]\]. The rats (*n* = 16) were randomly assigned into two groups. The morphine-tolerant group received two 75 mg morphine sulfate pellets (NIDA, Rockville, MD, USA) on Day 1 via subcutaneous (s.c.) implantation and four pellets on Day 2, whereas the control group received placebo pellets on both days. On Day 5, the two groups were randomly assigned to receive either LPS (250 µg/kg, Sigma, St. Louis, MO, USA) or saline (vehicle) \[[@B5-brainsci-07-00014],[@B21-brainsci-07-00014],[@B22-brainsci-07-00014],[@B23-brainsci-07-00014],[@B24-brainsci-07-00014]\]. Thus, the four experimental groups were placebo-control + saline, placebo-control + LPS, morphine-tolerant + saline, and morphine-tolerant + LPS. Two hours after the treatment with LPS or saline, the animals were euthanized and the brains were harvested.

2.3. RNA Isolation and Preparation of cDNA {#sec2dot3-brainsci-07-00014}
------------------------------------------

Total RNA was extracted from the brain tissue using TRIZOL (Invitrogen, Carlsbad, CA, USA), following the manufacturer's protocol. To remove contaminating DNA, the total RNA samples were treated with RNase-free DNase (Qiagen, Valencia, CA, USA), followed by further purification using an RNeasy Mini Kit (Qiagen, Valencia, CA, USA). The RNA quality and quantity were assessed using a nanodrop spectrophotometer (Thermo Scientific, Waltham, MA, USA). An equal amount of RNA (400 ng) from each sample was then converted into first-strand cDNA using a RT^2^ First Strand Kit (SABiosciences, Frederick, MD, USA) for a PCR array.

2.4. Real-Time PCR Array {#sec2dot4-brainsci-07-00014}
------------------------

The expression of 84 key genes involved in the function of inflammasomes, general NLR signaling, and cytokine and chemokine genes was quantified using a custom PCR array and RT^2^ SYBR Green Fluorescein qPCR Master Mix (SABiosciences, Frederick, MD, USA), according to the manufacturer's protocol. Using an ABI Prism 7900HT Fast Detection System (Applied Biosystems, Foster, CA, USA), real-time PCR was performed by first denaturing the PCR mix at 95 °C for 10 min, followed by 40 cycles at 95 °C for 15 s and at 60 °C for 1 min.

2.5. PCR Array Data Analysis {#sec2dot5-brainsci-07-00014}
----------------------------

The expression of each gene was normalized to housekeeping genes and calculated using the ∆∆*C*t method. The threshold and baseline values were set manually, and the resulting threshold cycle values (*C*t) were analyzed using the PCR array data analysis template supplied on the manufacturer's website \[[@B25-brainsci-07-00014]\]. The mean fold change in mRNA expression from 3 to 5 biological replicates was considered significant at *p* \< 0.05. The gene profile signatures were created for every two groups compared.

2.6. LINCS Analysis {#sec2dot6-brainsci-07-00014}
-------------------

The differentially expressed genes were input into the Query App (apps.lincscloud.org/query), as described previously \[[@B26-brainsci-07-00014],[@B27-brainsci-07-00014]\]. Based on the LINCS database, LincsCloud utilized gene profile signatures generated from the PCR array to generate a report, including probability outcomes in terms of gene knockdown effects and drug mimics. The scores given in the report evaluated how much a particular set of gene regulation features (named pertubagens) was likely to be connected with the genes listed in the LINCS report. Positive readings in the Consensus Knockdown Connections in the report indicate that knockdown of the genes listed in the LINCS report would match the gene changes input into the Query App, and thus the genes with high scores represent potential target genes for the experimental treatment.

3. Results {#sec3-brainsci-07-00014}
==========

3.1. Expression Profile of Inflammasome-Related Genes Following an LPS Challenge, with and without Morphine Tolerance {#sec3dot1-brainsci-07-00014}
---------------------------------------------------------------------------------------------------------------------

Alterations in gene expression were measured in rats challenged with LPS, with and without morphine tolerance, using a PCR array containing 84 genes related to inflammasome activation and function. NLRP12 expression was significantly decreased in response to LPS in both the morphine-tolerant (morphine-tolerant + LPS) and control (placebo-control + LPS) rats, compared to the rats given saline (morphine-tolerant + saline and placebo-control + saline) ([Figure 1](#brainsci-07-00014-f001){ref-type="fig"}, [Table 1](#brainsci-07-00014-t001){ref-type="table"}). However, the decrease was greater in the placebo-control rats (−7.3 fold; *p* \< 0.01) than in the morphine-tolerant rats (−4.5 fold; *p* \< 0.05).

3.2. Expression Profile of Inflammasome-Related Downstream Signaling Genes Following an LPS Challenge, With and Without Morphine Tolerance {#sec3dot2-brainsci-07-00014}
------------------------------------------------------------------------------------------------------------------------------------------

With a few exceptions, there were no significant changes in expression of the downstream signaling genes in response to LPS in either the morphine-tolerant rats (morphine-tolerant + LPS) or the control animals (placebo-control + LPS), compared to the rats given saline (morphine-tolerant + saline and placebo-control + saline) ([Table 1](#brainsci-07-00014-t001){ref-type="table"}). However, Baculoviral IAP Repeat-Containing 3 (Birc3), an important regulator gene involved in the downstream effects of inflammasomes, was significantly increased in response to LPS in both the morphine-tolerant (21.5 fold; *p* \< 0.05) and control (21 fold; *p* \< 0.01) groups, compared to the rats given saline ([Figure 2](#brainsci-07-00014-f002){ref-type="fig"}, [Table 2](#brainsci-07-00014-t002){ref-type="table"}). In addition, NF-Kappa-B Inhibitor Alpha (Nfkbia), an inhibitor protein of NF-κB, was increased in both groups given LPS (morphine-tolerant + LPS, 3.4 fold, *p* \< 0.01; placebo-control + LPS, 3.9 fold, *p* \< 0.01) ([Figure 2](#brainsci-07-00014-f002){ref-type="fig"}, [Table 2](#brainsci-07-00014-t002){ref-type="table"}).

3.3. Expression Profile of Inflammasome-Related Chemokine and Cytokine Genes after an LPS Challenge, with and without Morphine Tolerance {#sec3dot3-brainsci-07-00014}
----------------------------------------------------------------------------------------------------------------------------------------

Cytokine and chemokine gene expression in response to LPS was greater in the control rats (placebo-control + LPS) compared to the morphine-tolerant animals (morphine-tolerant + LPS) ([Table 3](#brainsci-07-00014-t003){ref-type="table"}). The cytokines IL-1β and IL-6 were significantly increased 7- and 12-fold, respectively (*p* \< 0.01--0.001), in the control rats given LPS (placebo-control + LPS), whereas in the morphine-tolerant group (morphine-tolerant + LPS) the fold changes were not statistically significant (3- and 7-fold, respectively) compared to the rats given saline ([Figure 3](#brainsci-07-00014-f003){ref-type="fig"}, [Table 3](#brainsci-07-00014-t003){ref-type="table"}).

Similarly, Ccl2, Ccl7, Cxcl1, and Cxcl3 chemokine expression was significantly increased 24-, 11-, 37-, and 8-fold, respectively (*p* \< 0.01--0.001), in response to LPS in the control rats (placebo-control + LPS), whereas in the morphine-tolerant (morphine-tolerant + LPS) group the fold changes (9-, 7-, 14-, and 3-fold, respectively) were not statistically significant ([Figure 4](#brainsci-07-00014-f004){ref-type="fig"}, [Table 3](#brainsci-07-00014-t003){ref-type="table"}).

3.4. LINCS Analysis of the Differentially Expressed Genes {#sec3dot4-brainsci-07-00014}
---------------------------------------------------------

Differentially expressed genes in the morphine-tolerant + saline versus morphine-tolerant + LPS rats and in the placebo-control + saline versus placebo-control + LPS rats as well as gene changes in rats the placebo-control + saline versus morphine-tolerant + saline rats were input into the Query App (apps.lincscloud.org/query). One report was generated by LINCS for each set of genes input. The genes with a high positive score in Consensus Knockdown Connections were considered to be potential gene targets ([Table 4](#brainsci-07-00014-t004){ref-type="table"}). In the placebo-control + saline versus placebo-control + LPS report, VPS28, protein C receptor (PROCR), and charged multivesicular body protein 2A (CHMP2A) were the top three with the highest scores. VPS28 is an ESCRT-I complex subunit that functions in the transport and sorting of proteins into sub-cellular vesicles. PROCR is endothelial protein C receptor involved in the blood coagulation pathway. CHMP2A is a component of the endosomal sorting complex required for transport III, which is involved in the degradation of surface receptor proteins and the formation of endocytic multivesicular bodies.

In the placebo-control + saline versus morphine-tolerant + saline report, SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member 1 (SMARCE1), aryl-hydrocarbon receptor repressor (AHRR), and glutathione peroxidase 7 (GPX7) were the most likely targets predicted by LINCS. SMARCE1 is required for the transcriptional activation of genes normally repressed by chromatin. AHRR mediates dioxin toxicity and is involved in the regulation of cell growth and differentiation. GPX7 is involved with cellular senescence and insulin secretion.

In the morphine-tolerant + saline versus morphine-tolerant + LPS group, AHR (aryl hydrocarbon receptor), UBE2L6 (ubiquitin-conjugating enzyme E2L 6), and PAFAH1B3 (platelet-activating factor acetylhydrolase 1b, Catalytic Subunit 3) were the top three candidates. AHR is involved in the regulation of biological responses to planar aromatic hydrocarbons; UBE2L6 targets abnormal or short-lived proteins for degradation; and PAFAH1B3 functions in brain development and is associated with mental retardation, ataxia, and atrophy of the brain.

The predicted potential targets in each group were different from those in other groups, both in targets and their possibility rankings. VPS28 was the only one that appeared in both the Top 100 lists of placebo-control + saline versus placebo-control + LPS (No. 1 in [Table 4](#brainsci-07-00014-t004){ref-type="table"}) and morphine-tolerant + saline versus morphine-tolerant + LPS (No. 4 in [Table 4](#brainsci-07-00014-t004){ref-type="table"}).

[Table 4](#brainsci-07-00014-t004){ref-type="table"} shows the top three potential target genes from each set of gene comparisons. There was no similarity in the gene rankings in the three sets of gene comparisons.

4. Discussion {#sec4-brainsci-07-00014}
=============

Inflammasomes recognize a variety of pathogen-associated molecular patterns (PAMPs), including endotoxins such as LPS. Depending on the NLR proteins that constitute inflammasomes, an inflamasome can be pro-inflammatory or anti-inflammatory in nature \[[@B28-brainsci-07-00014]\]. For pro-inflammatory inflammasomes such as NLRP3, in vitro studies have shown that the activation and release of pro-inflammatory cytokines requires two signals. The first signal, triggered by PAMPs, leads to the activation of inflammasomes, which then provide the second signal. The activated inflammasomes, through caspase 1 activation, promote the production of the pro-inflammatory cytokines, IL-1β and IL-18. However, the signaling pathways during infection or inflammation in vivo are not yet completely defined \[[@B29-brainsci-07-00014]\], and the characteristics of anti-inflammatory inflammasomes such as NLRP12 have not yet been extensively investigated. To our knowledge, our study is one of the first to report the modulation of NLRP12 expression in response to LPS and morphine in vivo.

Recently, NLRP12 was designated as an anti-inflammatory NLR inflammasome protein. It is believed to be a negative regulator of the NF-κB signaling pathway by inhibiting downstream signaling of TLRs, particularly IRAK-1 \[[@B28-brainsci-07-00014],[@B30-brainsci-07-00014]\]. Our results showed that NLRP12 expression decreased in the brains of both the control (placebo-control + LPS) and morphine-tolerant (morphine-tolerant + LPS) rats in response to an LPS challenge, indicating that one of the mechanisms by which LPS induces an inflammatory response is by inhibiting the expression of the anti-inflammatory NLRP12 inflammasome.

Although NLRP12 expression was decreased in both groups given LPS, the decrease was significantly greater in the control rats than in the morphine-tolerant rats, which suggests that the LPS-induced NLRP12 decrease is countered during morphine tolerance. Hence morphine may also modulate NLRP12 activity, directly or indirectly, thereby exerting its immunosuppressive effects and opposing the LPS-induced decrease in NLRP12 in the presence of morphine tolerance.

Birc3, a downstream regulator of inflammasome signaling, is essential for controlling the synthesis of cytokines and chemokines in the inflammatory Mapk and NF-κB pathways. It is also required for inflammasome activation, subsequent caspase 1 activity, and IL-1β formation \[[@B31-brainsci-07-00014]\]. In our study, Birc3 expression was significantly increased in both the placebo-control and morphine-tolerant rats in response to LPS, indicating that LPS is able to induce an inflammatory response through Birc3 activity, following inhibition of the anti-inflammatory NLRP12. However, in response to LPS, Birc3 expression in the morphine-tolerant rats did not change in comparison to the placebo-control rats. This indicates that morphine may not be able to modulate Birc3 expression, and therefore there is no change, increase or decrease, in its expression in the morphine tolerant state.

NF-κB is important in the activation of inflammatory mediators such as cytokines and chemokines \[[@B16-brainsci-07-00014]\]. Previous studies have reported that NLRP12 inhibits both canonical and non-canonical NF-κB activation \[[@B16-brainsci-07-00014],[@B28-brainsci-07-00014]\] and that Nfkbia, a downstream regulator of inflammasomes, inhibits the activity of dimeric NF-κB/Rel complexes \[[@B32-brainsci-07-00014]\]. In our study, Nfkbia was significantly increased in response to LPS in both the placebo-control and morphine-tolerant rats. During an inflammatory response, one would expect the expression and activity of a positive regulator of inflammation to be increased, whereas that of a negative regulator would be decreased. However, from a physiological standpoint, there is a constant effort to balance pro- and anti-inflammatory activity \[[@B33-brainsci-07-00014],[@B34-brainsci-07-00014]\]. This quest to balance the pro- and anti-inflammatory responses could be one of the reasons for an increase in Nfkbia, which is known to inhibit the activity of the pro-inflammatory dimeric NF-κB/REL, thus reducing the production of pro-inflammatory mediators.

As expected, we found that the expression of pro-inflammatory cytokines (IL-1β and IL-6) and chemokines (Ccl2, Ccl7, Cxcl1, and Cxcl3) was increased in response to LPS in the placebo-control rats \[[@B35-brainsci-07-00014],[@B36-brainsci-07-00014],[@B37-brainsci-07-00014]\]. In the morphine-tolerant rats, however, the LPS-induced cytokine and chemokine expression levels were lower, suggesting that NLRP12 inhibition in response to LPS may be opposed or subdued in the morphine tolerant state.

In a previous study, we observed that, in peripheral immune organs such as the spleen, NLRP3 expression, but not NLRP12 expression, is altered in response to LPS, with and without morphine tolerance \[[@B38-brainsci-07-00014]\], suggesting that the mechanism(s) of inflammasome activation in response to pathogens may be different in peripheral immune organs, compared to the central nervous system. During morphine tolerance, the LPS-induced expression of NLRP3, as well as that of cytokines and chemokines, is reduced in comparison to the placebo-control rats given LPS \[[@B38-brainsci-07-00014]\]. These observations are consistent with previous studies showing that immune activation, including an inflammatory response, is diminished during morphine tolerance \[[@B39-brainsci-07-00014]\]. Therefore, the data from the present study, as well as from our previous report \[[@B38-brainsci-07-00014]\], collectively indicate that morphine may exert its effects through both pro- and anti-inflammatory inflammasomes.

LINCS analysis is able to predict potential target genes based on a certain treatment and the gene profile signatures in its database. In our study, LINCS was able to generate a report of potential targets with a *p* value of \<0.05 from the list of genes with altered expression in response to LPS in control rats (placebo-control + saline versus placebo-control + LPS) but not from the other two comparisons (placebo-control + saline versus morphine-tolerant + saline, morphine-tolerant + saline versus morphine-tolerant + LPS), because there were not enough significant gene features in those two groups. When enlarging the set of gene features for the comparison of placebo-control + saline versus placebo-control + LPS to a *p*-value of \<0.1, LINCS generated a report with similar potential targets. Thus, the gene features were then studied with a *p*-value of \<0.1 on all three sets of comparisons. VPS28, PROCR, and CHMP2A were the top three with the highest scores in LINCS report generated based on placebo-control + saline versus placebo-control + LPS gene alternations, suggesting that Vps28, Procr and Chmp2a were potential targets of LPS. In the report for placebo-control + saline versus morphine-tolerant + saline, SMARCE1, AHRR, and GPX7 were the most likely targets altered in morphine tolerance predicted by LINCS. In the morphine-tolerant + saline versus morphine-tolerant + LPS report, AHR, UBE2L6, and PAFAH1B3 were the top three candidates that potentially responsible for the LPS-induced immune responses during morphine tolerance in rats. In the LINCS reports, the listed potential targets had different rankings using the different sets of gene features. This confirms that the response to LPS by those inflammosome-related genes could be affected by morphine tolerance.

Moreover, among the targets listed above, while VPS28 was No. 1 in the control rats in response to LPS, it was No. 4 in morphine-tolerant rats ([Table 4](#brainsci-07-00014-t004){ref-type="table"}). The VPS28 protein functions in transporting and sorting proteins into sub-cellular vesicles. In our study, LINCS analysis suggests that the actions of VPS28 in response to LPS could be dampened during morphine tolerance.

5. Conclusions {#sec5-brainsci-07-00014}
==============

The results from our study indicate that, in the rat brain, LPS-induced inflammation involves both the inhibition of the NLRP12 anti-inflammatory inflammasome and the stimulation of downstream regulators such as Birc3, thereby increasing the expression of pro-inflammatory chemokines and cytokines. However, in the morphine tolerant state, the response to LPS is dampened, as indicated by the reduced expression of inflammasome-related genes. LINCS analysis confirmed that the response to LPS is altered during morphine tolerance and indicated that VPS28 may be one of the genes responsible for the alterations associated with morphine tolerance.
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Genes analyzed in PCR Array.

  Gene Symbol   Full Name                                                                     mRNA Entry
  ------------- ----------------------------------------------------------------------------- ----------------
  Card6         caspase recruitment domain family, member 6                                   NM_001106413.1
  Casp1         caspase 1                                                                     NM_012762.2
  Casp12        caspase 12                                                                    NM_130422.1
  Casp8         caspase 8                                                                     NM_022277.1
  Naip2         NLR family, apoptosis inhibitory protein 6                                    XM_008760697.2
  Nlrp12        NLR family, pyrin domain containing 12                                        NM_001169142.1
  Nlrp5         NLR family, pyrin domain containing 5                                         NM_001107474.1
  Nlrc4         NLR family, CARD domain containing 4                                          NM_001309432.1
  Nlrp1a        NLR family, pyrin domain containing 1A                                        NM_001145755.2
  Nlrp3         NLR family, pyrin domain containing 3                                         NM_001191642.1
  Nlrp6         NLR family, pyrin domain containing 6                                         NM_134375.3
  Nlrx1         NLR family member X1                                                          NM_001025010.1
  Nod2          nucleotide-binding oligomerization domain containing 2                        NM_001106172.1
  Pycard        PYD and CARD domain containing                                                NM_172322.1
  Bcl2          BCL2, apoptosis regulator                                                     NM_016993.1
  Bcl2l1        BCL2 like 1                                                                   NM_001033670.1
  Birc2         baculoviral IAP repeat-containing 2                                           NM_021752.2
  Birc3         baculoviral IAP repeat-containing 3                                           NM_023987.3
  Cflar         CASP8 and FADD-like apoptosis regulator                                       NM_001033864.2
  Chuk          conserved helix-loop-helix ubiquitous kinase                                  NM_001107588.1
  Ciita         class II, major histocompatibility complex, transactivator                    NM_001270803.1
  Ctsb          cathepsin B                                                                   NM_022597.2
  Fadd          Fas associated via death domain                                               NM_152937.2
  Hsp90aa1      heat shock protein 90, alpha (cytosolic), class A member 1                    NM_175761.2
  Hsp90ab1      heat shock protein 90 alpha family class B member 1                           NM_001004082.3
  Ikbkb         inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta    NM_053355.2
  Ikbkg         inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma   NM_199103.1
  Irak1         interleukin-1 receptor-associated kinase 1                                    NM_001127555.1
  Map3k7        mitogen activated protein kinase kinase kinase 7                              NM_001107920.2
  Map3k7ip1     TGF-beta activated kinase 1/MAP3K7 binding protein 1                          NM_001109976.2
  Map3k7ip2     TGF-beta activated kinase 1/MAP3K7 binding protein 2                          NM_001012062.1
  Mapk1         mitogen activated protein kinase 1                                            NM_053842.2
  Mapk11        mitogen-activated protein kinase 11                                           NM_001109532.2
  Mapk12        mitogen-activated protein kinase 12                                           NM_021746.1
  Mapk13        mitogen activated protein kinase 13                                           NM_019231.2
  Mapk14        mitogen activated protein kinase 14                                           NM_031020.2
  Mapk3         mitogen activated protein kinase 3                                            NM_017347.2
  Mapk8         mitogen-activated protein kinase 8                                            NM_053829.2
  Mapk9         mitogen-activated protein kinase 9                                            NM_001270544.1
  Mefv          Mediterranean fever                                                           NM_031634.1
  Myd88         myeloid differentiation primary response 88                                   NM_198130.1
  Nfkb1         nuclear factor kappa B subunit 1                                              NM_001276711.1
  Nfkbia        NFKB inhibitor alpha                                                          NM_001105720.2
  Nfkbib        NFKB inhibitor beta                                                           NM_030867.2
  P2rx7         purinergic receptor P2X 7                                                     NM_019256.1
  Panx1         Pannexin 1                                                                    NM_001270548.1
  Pea15a        phosphoprotein enriched in astrocytes 15                                      NM_001013231.1
  Pstpip1       proline-serine-threonine phosphatase-interacting protein 1                    NM_001106824.2
  Ptgs2         prostaglandin-endoperoxide synthase 2                                         NM_017232.3
  Rage          MOK protein kinase                                                            NM_001010965.1
  Rela          RELA proto-oncogene, NF-kB subunit                                            NM_199267.2
  Ripk2         receptor-interacting serine-threonine kinase 2                                NM_001191865.1
  Sugt1         SGT1 homolog, MIS12 kinetochore complex assembly cochaperone                  NM_001013051.1
  Tirap         TIR domain containing adaptor protein                                         XM_017596001.1
  Hsp90b1       heat shock protein 90 beta family member 1                                    NM_001012197.2
  Traf6         TNF receptor associated factor 6                                              NM_001107754.2
  Txnip         thioredoxin interacting protein                                               NM_001008767.1
  Xiap          E3 ubiquitin-protein ligase XIAP                                              NM_022231.2
  Ccl11         C-C motif chemokine ligand 11                                                 NM_019205.1
  Ccl12         chemokine (C-C motif) ligand 12                                               NM_001105822.1
  Ccl2          C-C motif chemokine ligand 2                                                  NM_031530.1
  Ccl5          C-C motif chemokine ligand 5                                                  NM_031116.3
  Ccl7          C-C motif chemokine ligand 7                                                  NM_001007612.1
  Cxcl1         C-X-C motif chemokine ligand 1                                                NM_030845.1
  Cxcl3         C-X-C motif chemokine ligand 3                                                NM_138522.1
  Cd40lg        CD40 ligand                                                                   NM_053353.1
  Ifnb1         interferon beta 1                                                             NM_019127.1
  Ifng          interferon gamma                                                              NM_138880.2
  Il12a         interleukin 12A                                                               NM_053390.1
  Il12b         interleukin 12B                                                               NM_022611.1
  Il18          interleukin 18                                                                NM_019165.1
  Il1b          interleukin 1 beta                                                            NM_031512.2
  Il33          interleukin 33                                                                NM_001014166.1
  Il6           interleukin 6                                                                 NM_012589.2
  Irf1          interferon regulatory factor 1                                                NM_012591.1
  Irf2          interferon regulatory factor 2                                                NM_001047086.1
  Irf3          interferon regulatory factor 3                                                NM_001006969.1
  Irf4          interferon regulatory factor 4                                                NM_001106108.1
  Irf5          interferon regulatory factor 5                                                NM_001106586.1
  Irf6          interferon regulatory factor 6                                                NM_001108859.1
  Tnfsf11       tumor necrosis factor superfamily member 11                                   NM_057149.1
  Tnfsf14       tumor necrosis factor superfamily member 14                                   NM_001191803.1
  Tnfsf4        tumor necrosis factor superfamily member 4                                    NM_053552.1

brainsci-07-00014-t006

###### 

Top 10 scored Genes in LINCS report.

  Gene Symbol   Full name
  ------------- ---------------------------------------------------------------------------------------------------
  VPS28         VPS28, ESCRT-I subunit
  PROCR         protein C receptor
  CHMP2A        charged multivesicular body protein 2A
  MB            myoglobin
  ZNF768        zinc finger protein 768
  RBPJ          recombination signal binding protein for immunoglobulin kappa J region
  WARS2         tryptophanyl tRNA synthetase 2 (mitochondrial)
  TBX2          T-box 2
  MRPS2         mitochondrial ribosomal protein S2
  MAP3K14       mitogen-activated protein kinase kinase kinase 14
  SMARCE1       SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member 1
  AHRR          aryl-hydrocarbon receptor repressor
  GPX7          glutathione peroxidase 7
  ATP5F1        ATP synthase, H+ transporting, mitochondrial Fo complex subunit B1
  CALR          calreticulin
  GPR110        G protein-coupled receptor 110
  ELF4          E74 like ETS transcription factor 4
  FGFR1         fibroblast growth factor receptor 1
  F7            coagulation factor VII
  AHR           aryl hydrocarbon receptor
  UBE2L6        ubiquitin-conjugating enzyme E2L 6
  PAFAH1B3      platelet-activating factor acetylhydrolase 1b, catalytic subunit 3
  JUNB          JunB proto-oncogene, AP-1 transcription factor subunit
  RYK           receptor-like tyrosine kinase
  ARG1          arginase 1
  ZNF324        zinc finger protein 324
  ATP5D         ATP synthase, H+ transporting, mitochondrial F1 complex, delta subunit

![Inflammasome-related gene expression in the rat brain in response to lipopolysaccharide (LPS), with and without morphine tolerance. The expression of the inflammasome-related NOD-like receptor (NLR) genes (Naip2, Nlrp12, Nlrp5, Nlrc4, Nlrp1a, Nlrp3, Nlrp6, And Nlrx1) in the brains of rats given an i.p. injection of either 250 µg/kg LPS or saline, with and without morphine tolerance (*n* = 3--5 rats per group), was determined using a PCR array. Data were calculated using the ΔΔCT method, relative to the control group (placebo-control +saline), and are represented as a fold change. \* *p* \< 0.05, \*\* *p* \< 0.01. Naip2: NLR family, apoptosis inhibitory protein 6; Nlrp12: NLR Family Pyrin Domain Containing 12; Nlrp5: NLR Family Pyrin Domain Containing 5; Nlrc4: NLR Family CARD Domain Containing 4; Nlrp1a: NLR family, pyrin domain containing 1A; Nlrp3: NLR Family Pyrin Domain Containing 3; Nlrp6: NLR Family Pyrin Domain Containing 6; Nlrpx1: NLR family member X1.](brainsci-07-00014-g001){#brainsci-07-00014-f001}

![Inflammasome-related downstream gene expression in the rat brain in response to Lipopolysaccharides (LPS), with and without morphine tolerance. The expression of the inflammasome-related downstream signaling genes Baculoviral IAP Repeat-Containing 3 (Birc3) and NF-Kappa-B Inhibitor Alpha (Nfkbia) in the brains of rats given an i.p. injection of either 250 µg/kg LPS or saline, with and without morphine tolerance (*n* = 3--5 rats per group), was determined using a Polymerase Chain Reaction (PCR) array. The data were calculated using the ΔΔ*C*T method relative to the control group (placebo-control + saline) and are represented as fold change.](brainsci-07-00014-g002){#brainsci-07-00014-f002}

![Cytokine gene expression in the rat brain in response to lipopolysaccharides (LPS), with and without morphine tolerance. Gene expression of interleukins Interleukin (Il)-1β, Il-6, Il-12a, Il-12b, Il-18, and Il-33 in the brains of rats, with and without morphine tolerance, following an i.p. injection of either 250 µg/kg LPS or saline (*n* = 3--5 rats per group) was determined using a Polymerase Chain Reaction (PCR) array. Data were calculated using the ΔΔCT method relative to the control group (placebo-control + saline) and are represented as a fold change. \* *p* \< 0.05, \*\* *p* \< 0.01, \*\*\* *p* \< 0.001](brainsci-07-00014-g003){#brainsci-07-00014-f003}

![Chemokine gene expression in the rat brain in response to Lipopolysaccharides (LPS), with and without morphine tolerance. Gene expression of the chemokines C-C motif chemokine ligand (Ccl)2, Ccl5, Ccl7, Ccl11, Ccl12, C-X-C motif chemokine ligand (Cxcl)1, and Cxcl3 in the brains of rats with and without morphine tolerance, following an i.p. injection of either 250 µg/kg LPS or saline (*n* = 3--5 rats per group), was determined using a Polymerase Chain Reaction (PCR) array. Data were calculated using the ΔΔCT method relative to the control group (placebo-control + saline) and are represented as a fold change. \* *p* \< 0.05, \*\* *p* \< 0.01, \*\*\* *p* \< 0.001](brainsci-07-00014-g004){#brainsci-07-00014-f004}

brainsci-07-00014-t001_Table 1

###### 

Expression profile of inflammasomes and NLR genes in the rat brain in response to lipopolysaccharides (LPS), with and without morphine tolerance.

           morphine-tolerant + saline/placebo control + saline   placebo control + LPS/placebo control + saline   morphine-tolerant + LPS/morphine-tolerant + saline                        
  -------- ----------------------------------------------------- ------------------------------------------------ ---------------------------------------------------- ---------- --------- ----------
  Card6    −1.2347                                               0.078926                                         −1.5292                                              0.004159   −1.714    0.017499
  Casp1    1.1505                                                0.299299                                         1.2132                                               0.276593   1.2764    0.02969
  Casp12   1.0972                                                0.462347                                         1.5422                                               0.003614   1.4249    0.092085
  Casp8    −1.0402                                               0.612597                                         −1.1363                                              0.391056   −1.2652   0.139999
  Naip2    −1.4483                                               0.067329                                         −1.1031                                              0.619799   −1.2316   0.25758
  Nlrp12   −1.6504                                               0.674422                                         −7.31                                                0.002731   −4.5124   0.025372
  Nlrp5    1.494                                                 0.054876                                         1.274                                                0.20786    1.2819    0.027352
  Nlrc4    1.0028                                                0.915792                                         1.1349                                               0.159712   1.1003    0.445719
  Nlrp1a   −1.0898                                               0.470844                                         −1.2027                                              0.001147   −1.3308   0.1379
  Nlrp3    1.3773                                                0.134647                                         1.5114                                               0.054565   1.3956    0.02407
  Nlrp6    1.205                                                 0.420019                                         −1.6225                                              0.358997   1.0293    0.784547
  Nlrx1    −1.1574                                               0.24832                                          −1.1494                                              0.191026   1.039     0.679959
  Nod2     −1.6257                                               0.650152                                         1.0901                                               0.811946   1.2826    0.50395
  Pycard   −1.0575                                               0.610143                                         −1.0285                                              0.797363   −1.2363   0.030115

\* For *p*-value, letters in red mean *p* \< 0.05. \*\* For Fold Change, letters in red mean fold change \>2 and letters in blue mean the fold change \<−2. For the color lines, ![](brainsci-07-00014-i001.jpg): 6--10 fold decrease; ![](brainsci-07-00014-i002.jpg): 2--5 fold decrease; ![](brainsci-07-00014-i003.jpg): \<2 fold; ![](brainsci-07-00014-i004.jpg): 2--5 fold increase; ![](brainsci-07-00014-i005.jpg): 6--10 fold increase; ![](brainsci-07-00014-i006.jpg): 11--30 fold increase; ![](brainsci-07-00014-i007.jpg): 31--50 fold increase.

brainsci-07-00014-t002_Table 2

###### 

Expression profile of inflammasome-related downstream signaling genes in the rat brain in response to lipopolysaccharides (LPS), with and without morphine tolerance. Full name of the genes were provided in [Appendix Table A1](#brainsci-07-00014-t005){ref-type="table"}.

              morphine-tolerant + saline/placebo control + saline   placebo control + LPS/placebo control + saline   morphine-tolerant + LPS/morphine-tolerant + saline                        
  ----------- ----------------------------------------------------- ------------------------------------------------ ---------------------------------------------------- ---------- --------- ----------
  Bcl2        1.0469                                                0.863233                                         1.0586                                               0.845254   1.2398    0.339246
  Bcl2l1      −1.1256                                               0.01111                                          1.0572                                               0.476643   −1.0291   0.671184
  Birc2       1.0509                                                0.586337                                         −1.0281                                              0.622487   1.0699    0.531417
  Birc3       1.0648                                                0.587513                                         20.9356                                              0.011065   21.5025   0.001873
  Cflar       1.0226                                                0.697346                                         1.3021                                               0.004748   1.2155    0.140978
  Chuk        1.1867                                                0.119108                                         −1.0233                                              0.754891   1.1593    0.073058
  Ciita       −1.0617                                               0.750879                                         1.0619                                               0.873363   1.4678    0.39646
  Ctsb        −1.0009                                               0.978499                                         −1.0656                                              0.617885   −1.1046   0.493204
  Fadd        −1.1261                                               0.258884                                         1.1235                                               0.252486   1.0306    0.71174
  Hsp90aa1    1.2774                                                0.114349                                         1.0391                                               0.743375   1.189     0.149024
  Hsp90ab1    1.0752                                                0.376876                                         −1.0968                                              0.305427   1.1579    0.18515
  Ikbkb       1.0718                                                0.550623                                         −1.0011                                              0.962992   1.1799    0.201955
  Ikbkg       1.0924                                                0.324904                                         −1.0402                                              0.492725   1.1419    0.079202
  Irak1       1.1549                                                0.062648                                         1.0287                                               0.755395   1.2213    0.242955
  Map3k7      −1.2495                                               0.002404                                         −1.1008                                              0.434596   −1.2497   0.114056
  Map3k7ip1   −1.0335                                               0.664499                                         −1.1151                                              0.369226   1.02      0.864431
  Map3k7ip2   −1.2869                                               0.000867                                         −1.1169                                              0.456355   −1.3427   0.007785
  Mapk1       −1.0527                                               0.468581                                         −1.0887                                              0.159097   1.0316    0.724595
  Mapk11      −1.0673                                               0.530192                                         −1.0706                                              0.578016   −1.0633   0.571223
  Mapk12      1.1424                                                0.420684                                         1.1889                                               0.372287   −1.0255   0.780819
  Mapk13      −1.1629                                               0.924422                                         −1.5423                                              0.355826   1.0504    0.651078
  Mapk14      1.0018                                                0.940725                                         −1.0318                                              0.81795    1.0335    0.709962
  Mapk3       −1.1294                                               0.224192                                         −1.121                                               0.372958   −1.0495   0.76638
  Mapk8       1.0383                                                0.883566                                         −1.0215                                              0.798267   1.0037    0.911563
  Mapk9       −1.1252                                               0.03886                                          −1.0075                                              0.87718    −1.0805   0.288977
  Mefv        1.2572                                                0.278807                                         1.2582                                               0.463496   1.9192    0.028283
  Myd88       1.0211                                                0.791137                                         1.0103                                               0.917416   1.2185    0.03802
  Nfkb1       1.1098                                                0.279116                                         1.2919                                               0.089881   1.3323    0.033357
  Nfkbia      −1.0294                                               0.835021                                         3.885                                                0.001215   3.3744    0.001348
  Nfkbib      −1.1473                                               0.330475                                         −1.0153                                              0.762037   −1.1167   0.643504
  P2rx7       −1.1586                                               0.428492                                         1.0742                                               0.625549   1.0578    0.661519
  Panx1       −1.076                                                0.275575                                         1.1455                                               0.406863   1.1101    0.334734
  Pea15a      −1.0943                                               0.291531                                         −1.043                                               0.625202   −1.0802   0.492135
  Pstpip1     −1.1041                                               0.527175                                         −1.1018                                              0.680263   −1.0232   0.87342
  Ptgs2       −1.08                                                 0.499364                                         1.5126                                               0.000571   1.1762    0.323717
  Rage        1.0729                                                0.478448                                         −1.1273                                              0.17423    1.1854    0.16574
  Rela        1.0171                                                0.804744                                         1.1801                                               0.417806   1.2504    0.106174
  Ripk2       −1.1057                                               0.237762                                         1.2913                                               0.028006   1.1199    0.389288
  Sugt1       1.0063                                                0.918273                                         −1.1023                                              0.519396   −1.1264   0.106262
  Tirap       −1.3098                                               0.094434                                         −1.0971                                              0.535721   1.0809    0.374146
  Hsp90b1     1.0475                                                0.680071                                         −1.0334                                              0.69801    −1.0877   0.314466
  Traf6       −1.0344                                               0.915204                                         −1.0171                                              0.943304   1.0988    0.437323
  Txnip       −1.0761                                               0.70951                                          −1.0718                                              0.699702   −1.0187   0.789181
  Xiap        1.0572                                                0.503462                                         −1.0558                                              0.471524   1.0089    0.93573

\* For *p*-value, letters in red mean *p* \< 0.05. \*\* For Fold Change, letters in red mean fold change \>2 and letters in blue mean the fold change \<−2. For the color line, ![](brainsci-07-00014-i008.jpg): 6--10 fold decrease; ![](brainsci-07-00014-i009.jpg): 2--5 fold decrease; ![](brainsci-07-00014-i010.jpg): \<2 fold; ![](brainsci-07-00014-i011.jpg): 2--5 fold increase; ![](brainsci-07-00014-i012.jpg): 6--10 fold increase; ![](brainsci-07-00014-i013.jpg): 11--30 fold increase; ![](brainsci-07-00014-i014.jpg): 31--50 fold increase.

brainsci-07-00014-t003_Table 3

###### 

Expression profile of the cytokine and chemokine genes in the rat brain in response to LPS, with and without morphine tolerance.

            morphine-tolerant + saline/placebo control + saline   placebo control + LPS/placebo control + saline   morphine-tolerant + LPS/morphine-tolerant + saline                        
  --------- ----------------------------------------------------- ------------------------------------------------ ---------------------------------------------------- ---------- --------- ----------
  Ccl11     −2.4662                                               0.023104                                         −2.8639                                              0.16576    −2.7346   0.249229
  Ccl12     −1.4362                                               0.646529                                         2.0214                                               0.219015   2.1108    0.399119
  Ccl2      1.1756                                                0.521412                                         23.7845                                              0.001354   9.1497    0.106064
  Ccl5      −1.105                                                0.472434                                         1.2909                                               0.290174   −1.0949   0.766893
  Ccl7      −1.0841                                               0.688167                                         10.7188                                              0.000259   6.9528    0.163034
  Cxcl1     1.0131                                                0.944854                                         36.8609                                              0          14.4718   0.130008
  Cxcl3     1.6208                                                0.019673                                         8.1909                                               0.000076   3.6477    0.170486
  Cd40lg    −2.2796                                               0.215753                                         1.1119                                               0.704126   −2.4054   0.273798
  Ifnb1     1.2519                                                0.936419                                         1.6899                                               0.391302   1.5695    0.513801
  Ifng      1.5355                                                0.290413                                         1.1698                                               0.767882   2.2615    0.088346
  Il12a     1.05                                                  0.57557                                          1.1178                                               0.33855    1.0837    0.456191
  Il12b     2.5587                                                0.26828                                          8.1055                                               0.102341   2.077     0.198782
  Il18      1.068                                                 0.60015                                          1.0484                                               0.707002   −1.1151   0.48359
  Il1b      −1.2476                                               0.284501                                         6.7366                                               0.001383   3.3136    0.089312
  Il33      1.2342                                                0.054615                                         1.0407                                               0.583823   1.1978    0.072613
  Il6       2.023                                                 0.45937                                          12.0303                                              0.008058   7.0943    0.083969
  Irf1      1.1299                                                0.521156                                         3.4575                                               0.000386   3.4104    0.01276
  Irf2      −1.1481                                               0.050782                                         1.0027                                               0.916481   1.0556    0.593809
  Irf3      −1.2824                                               0.024657                                         −1.3225                                              0.225481   −1.2478   0.088625
  Irf4      −1.1491                                               0.43182                                          −1.0557                                              0.846866   1.0263    0.858979
  Irf5      −1.1024                                               0.38296                                          −1.1468                                              0.376953   1.0391    0.841777
  Irf6      1.1055                                                0.413463                                         1.012                                                0.792025   1.118     0.272222
  Tnfsf11   −1.6077                                               0.800779                                         −1.362                                               0.519436   −1.3266   0.965379
  Tnfsf14   −1.396                                                0.243156                                         −1.8445                                              0.126355   −1.4278   0.629476
  Tnfsf4    −1.0175                                               0.997398                                         −1.0887                                              0.790199   −1.3422   0.420711

\* For *p*-value, letters in red mean *p* \< 0.05. \*\* For Fold Change, letters in red mean fold change \>2 and letters in blue mean the fold change \<−2. For the color lines, ![](brainsci-07-00014-i015.jpg): 6--10 fold decrease; ![](brainsci-07-00014-i016.jpg): 2--5 fold decrease; ![](brainsci-07-00014-i017.jpg): \<2 fold; ![](brainsci-07-00014-i018.jpg): 2--5 fold increase; ![](brainsci-07-00014-i019.jpg): 6--10 fold increase; ![](brainsci-07-00014-i020.jpg): 11--30 fold increase; ![](brainsci-07-00014-i021.jpg): 31--50 fold increase.

brainsci-07-00014-t004_Table 4

###### 

LINCS Consensus Knockdown Connections from differentially expressed genes in the rat brain in response to lipopolysaccharides (LPS), with and without morphine tolerance. (A) Top 10 Consensus Knockdown Connections in the three sets of gene comparisons; (B) Rankings of the top three Consensus Knockdown Connections in the three sets of gene comparisons. Full name of the genes were provided in [Appendix Table A2](#brainsci-07-00014-t006){ref-type="table"}.

  ----------- --------------- ------------------------------------ ------------------------------------------------- --------------------------------------------------------
  \(A\)       **Rank**        **placebo-Saline vs. Placebo-LPS**   **Placebo-Saline vs. Morphine-Tolerant-Saline**   **Morphine-Tolerant-Saline vs. Morphine-Tolerant-LPS**
  1           VPS28           SMARCE1                              AHR                                               
  2           PROCR           AHRR                                 UBE2L6                                            
  3           CHMP2A          GPX7                                 PAFAH1B3                                          
  4           MB              ATP5F1                               VPS28                                             
  5           ZNF768          CALR                                 JUNB                                              
  6           RBPJ            GPR110                               RYK                                               
  7           WARS2           CHMP2A                               ARG1                                              
  8           TBX2            ELF4                                 PROC                                              
  9           MRPS2           FGFR1                                ZNF324                                            
  10          MAP3K14         F7                                   ATP5D                                             
  \(B\)       **Gene Rank**   **Placebo-Saline vs. Placebo-LPS**   **Placebo-Saline vs. Morphine-Tolerant-Saline**   **Morphine-Tolerant-Saline vs. Morphine-Tolerant-LPS**
  VPS28       1               42                                   4                                                 
  PROCR       2               491                                  681                                               
  CHMP2A      3               7                                    177                                               
  SMARCE1-1   675             1                                    504                                               
  AHRR        2383            2                                    460                                               
  GPX7        488             3                                    2137                                              
  AHR         46              769                                  1                                                 
  UBE2L6      89              545                                  2                                                 
  PAFAH1B3    95              622                                  3                                                 
  ----------- --------------- ------------------------------------ ------------------------------------------------- --------------------------------------------------------
